Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study

Nuclear Medicine and Molecular Imaging

Volumn 46, Issue 1, 2012, Pages 48-56

  Lee, Jai Hyuen ^a   Lee, Won Ae ^a   Park, Seok Gun ^a   Park, Dong Kook ^a   Namgung, Hwan ^a  

^a Dankook University College of Medicine   (South Korea)

Author keywords

Colorectal cancer; Dual time point imaging; FDG PET; Glucose transporter; Hexokinase

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BETA CATENIN; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 84862992020     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-011-0120-x     Document Type: Article

References (33)

1. Sorensen M, Mortensen FV, Hoyer M, Vilstrup H, Keiding S. FDG-PET improves management of patients with colorectal liver metastases allocated for local treatment: a consecutive prospective study. Scand J Surg. 2007; 96: 209-13.
2. Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med. 2009; 50: 1036-41.
3. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004; 231: 305-32.
4. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18 F-FDG PET in oncology. J Nucl Med. 2008; 49: 480-508.
5. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999; 26: 1345-8.
6. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18 F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001; 42: 1412-7.
7. Houseni M, Chamroonrat W, Zhuang J, Gopal R, Alavi A, Zhuang H. Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med. 2010; 51: 535-42.
8. Nishiyama Y, Yamamoto Y, Kimura N, Ishikawa S, Sasakawa Y, Ohkawa M. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer. Ann Nucl Med. 2008; 22: 245-50.
9. Uesaka D, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Sasaki M, et al. Evaluation of dual-time-point 18 F-FDG PET for staging in patients with lung cancer. J Nucl Med. 2008; 49: 1606-12.
10. Kim S, Chung JK, Kim BT, Kim SJ, Jeong JM, Lee DS, et al. Relationship between Gastrointestinal F-18-fluorodeoxyglucose Accumulation and Gastrointestinal Symptoms in Whole-Body PET. Clin Positron Imaging. 1999; 2: 273-9.
11. Chung JK, Lee YJ, Kim C, Choi SR, Kim M, Lee K, et al. Mechanisms related to [18 F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. J Nucl Med. 1999; 40: 339-46.
12. Lyshchik A, Higashi T, Hara T, Nakamoto Y, Fujimoto K, Doi R, et al. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest. 2007; 25: 154-62.
13. Akhurst T, Kates TJ, Mazumdar M, Yeung H, Riedel ER, Burt BM, et al. Recent chemotherapy reduces the sensitivity of [18 F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005; 23: 8713-6.
14. Burt BM, Humm JL, Kooby DA, Squire OD, Mastorides S, Larson SM, et al. Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia. 2001; 3: 189-95.
15. Nassar A, Amin MB, Sexton DG, Cohen C. Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol. 2005; 13: 252-5.
16. Jiang Z, Fanger GR, Banner BF, Woda BA, Algate P, Dresser K, et al. A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev. 2003; 27: 422-6.
17. Chen S, Liu J, Li G, Mo F, Xu X, Zhang T, et al. Altered distribution of beta-catenin and prognostic roles in colorectal carcinogenesis. Scand J Gastroenterol. 2008; 43: 456-64.
18. Han SA, Chun H, Park CM, Kang SJ, Kim SH, Sohn D, et al. Prognostic significance of beta-catenin in colorectal cancer with liver metastasis. Clin Oncol (R Coll Radiol). 2006; 18: 761-7.
19. Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WL. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res. 2004; 10: 1401-8.
20. Sahlmann CO, Siefker U, Lehmann K, Meller J. Dual time point 2-[18 F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl Med Commun. 2004; 25: 819-23.
21. Sathekge MM, Maes A, Pottel H, Stoltz A, van de Wiele C. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J. 2010; 100: 598-601.
22. Umeda Y, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Saito Y, et al. Dual-time-point 18 F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging. 2009; 36: 1121-30.
23. Umeda Y, Demura Y, Morikawa M, Ameshima S, Tsuchida T, Fujibayashi Y, et al. Prognostic value of dual time point (18) F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis. Respirology. 2011; 16: 713-20.
24. Sanghera B, Wong WL, Lodge MA, Hain S, Stott D, Lowe J, et al. Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun. 2005; 26: 861-7.
25. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998; 83: 34-40.
26. Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res. 1996; 2: 1151-4.
27. Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer. 2001; 37: 204-9.
28. Lim SC, Lee TB, Choi CH, Ryu SY, Min YD, Kim KJ. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol. 2008; 97: 51-6.
29. Okubo R, Masuda H, Nemoto N. p53 mutation found to be a significant prognostic indicator in distal colorectal cancer. Oncol Rep. 2001; 8: 509-14.
30. Kaklamanis L, Savage A, Whitehouse R, Doussis-Anagnostopoulou I, Biddolph S, Tsiotos P, et al. Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer. Br J Cancer. 1998; 77: 1864-9.
31. Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002; 43: 173-80.
32. max in the delayed scan is correlated with elevated VEGF/VPF expression in the tumors. Skeletal Radiol. 2009; 38: 261-6.
33. Prante O, Maschauer S, Fremont V, Reinfelder J, Stoehr R, Szkudlinski M, et al. Regulation of uptake of 18 F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. J Nucl Med. 2009; 50: 1364-70.